News from intra-cellular therapies, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 18, 2014, 16:00 ET

Intra-Cellular Therapies to Announce 2013 Fourth Quarter And Full Year Financial Results and to Host Conference Call on Tuesday, March 25, at 4:30 pm Eastern Time

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system...

Mar 10, 2014, 07:30 ET

Intra-Cellular Therapies Announces the Appointment of Juan Sanchez, M.D., as Vice President of Corporate Communications and Investor Relations

 Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous...

Mar 03, 2014, 07:00 ET

Intra-Cellular Therapies Announces Initiation of Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients with Dementia, Including Alzheimer's Disease

 Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous...

Feb 26, 2014, 16:00 ET

Intra-Cellular Therapies to Present at the Cowen and Company 34th Annual Healthcare Conference

  Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced Dr. Sharon Mates, Ph.D., President and Chief Executive Officer, will present at...

Feb 07, 2014, 08:00 ET

Intra-Cellular Therapies to Present at Two Upcoming Healthcare Conferences

 Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced Dr. Sharon Mates, Ph.D., President and Chief Executive Officer, will present at...

Feb 05, 2014, 13:04 ET

Intra-Cellular Therapies Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares

 Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, today...

Jan 30, 2014, 21:15 ET

Intra-Cellular Therapies Announces Pricing of Public Offering of Common Stock; To Begin Trading on NASDAQ Global Select Market under "ITCI"

 Intra-Cellular Therapies, Inc. (OTCQB: ITCI), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, today...

Dec 19, 2013, 19:25 ET

Intra-Cellular Therapies Cleared for Quotation on OTCQB

 Intra-Cellular Therapies, Inc. ("ITI"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, announced...

Dec 09, 2013, 06:55 ET

Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia

Intra-Cellular Therapies, Inc. ("we," "ITI" or "the Company"), a biopharmaceutical company focused on the development of therapeutics for central...

Sep 03, 2013, 08:00 ET

Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger

 Intra-Cellular Therapies, Inc. ("ITI" or the "Company"), a biopharmaceutical company focused on the development of therapeutics for CNS...

May 14, 2013, 07:30 ET

Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors

 Intra-Cellular Therapies, Inc. ("ITI"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, is pleased...

Feb 19, 2013, 07:30 ET

Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings

 Intra-Cellular Therapies, Inc. ("ITI") today announced the completion of a Phase I single rising dose study of its phosphodiesterase 1...

Mar 02, 2011, 19:06 ET

Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia

Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda"), today announced that they have entered into...

Oct 01, 2010, 07:30 ET

Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease

Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002...

Jul 29, 2010, 09:00 ET

Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia

Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the...

Dec 21, 2009, 07:30 ET

Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase...

Mar 10, 2009, 07:30 ET

Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

'Trial Meets Primary and Key Secondary Endpoints' Intra-Cellular Therapies, Inc. today announced the final results from the ITI-007 Phase II trial...

Jan 13, 2009, 07:30 ET

Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

"Trial Concluded Early Due to Achievement of Statistical Significance Demonstrated at the Primary Endpoint" Intra-Cellular Therapies, Inc. today...

Apr 09, 2008, 01:00 ET

Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007

NEW YORK, April 9, 2008 /PRNewswire/ -- Intra-Cellular Therapies, Inc., today announced additional preclinical data from its ongoing development...

Feb 15, 2008, 00:00 ET

Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders

NEW YORK, Feb. 15 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (ITI), announced the presentation of preclinical data on ITI-007, its...